| Id: | acc2171 |
| Group: | 2sens |
| Protein: | PELP1 |
| Gene Symbol: | PELP1 |
| Protein Id: | Q8IZL8 |
| Protein Name: | PELP1_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser1033 |
| Site Sequence: | PTLAPEALPSQGEVEREGESP |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | ZR75 |
| Disease Info: | |
| Drug: | etoposide |
| Drug Info: | "Etoposide is a chemotherapeutic agent that inhibits topoisomerase II, leading to DNA strand breaks and apoptosis, and is used in the treatment of various cancers including small cell lung cancer, testicular cancer, and lymphomas, administered intravenously or orally." |
| Effect: | increase |
| Effect Info: | Protein phosphorylation enhances the sensitivity to drug therapy. |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 24786831 |
| Sentence Index: | 24786831_4-5 |
| Sentence: | "PELP1 is phosphorylated at Serine1033 by various DDR kinases like ataxia-telangiectasia mutated, ataxia telangiectasia and Rad3-related or DNAPKc and this phosphorylation of PELP1 is important for p53 coactivation functions. PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation." |
Sequence & Structure:
MAAAVLSGPSAGSAAGVPGGTGGLSAVSSGPRLRLLLLESVSGLLQPRTGSAVAPVHPPNRSAPHLPGLMCLLRLHGSVGGAQNLSALGALVSLSNARLSSIKTRFEGLCLLSLLVGESPTELFQQHCVSWLRSIQQVLQTQDPPATMELAVAVLRDLLRYAAQLPALFRDISMNHLPGLLTSLLGLRPECEQSALEGMKACMTYFPRACGSLKGKLASFFLSRVDALSPQLQQLACECYSRLPSLGAGFSQGLKHTESWEQELHSLLASLHTLLGALYEGAETAPVQNEGPGVEMLLSSEDGDAHVLLQLRQRFSGLARCLGLMLSSEFGAPVSVPVQEILDFICRTLSVSSKNISLHGDGPLRLLLLPSIHLEALDLLSALILACGSRLLRFGILIGRLLPQVLNSWSIGRDSLSPGQERPYSTVRTKVYAILELWVQVCGASAGMLQGGASGEALLTHLLSDISPPADALKLRSPRGSPDGSLQTGKPSAPKKLKLDVGEAMAPPSHRKGDSNANSDVCAAALRGLSRTILMCGPLIKEETHRRLHDLVLPLVMGVQQGEVLGSSPYTSSRCRRELYCLLLALLLAPSPRCPPPLACALQAFSLGQREDSLEVSSFCSEALVTCAALTHPRVPPLQPMGPTCPTPAPVPPPEAPSPFRAPPFHPPGPMPSVGSMPSAGPMPSAGPMPSAGPVPSARPGPPTTANHLGLSVPGLVSVPPRLLPGPENHRAGSNEDPILAPSGTPPPTIPPDETFGGRVPRPAFVHYDKEEASDVEISLESDSDDSVVIVPEGLPPLPPPPPSGATPPPIAPTGPPTASPPVPAKEEPEELPAAPGPLPPPPPPPPPVPGPVTLPPPQLVPEGTPGGGGPPALEEDLTVININSSDEEEEEEEEEEEEEEEEEEEEEDFEEEEEDEEEYFEEEEEEEEEFEEEFEEEEGELEEEEEEEDEEEEEELEEVEDLEFGTAGGEVEEGAPPPPTLPPALPPPESPPKVQPEPEPEPGLLLEVEEPGTEEERGADTAPTLAPEALPSQGEVEREGESPAAGPPPQELVEEEPSAPPTLLEEETEDGSDKVQPPPETPAEEEMETETEAEALQEKEQDDTAAMLADFIDCPPDDEKPPPPTEPDS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| PELP1-Ser1083 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.425 | ||||||||
| COAD | 0.214 | ||||||||
| HGSC | -1.918 | ||||||||
| ccRCC | |||||||||
| GBM | 1.326 | ||||||||
| HNSC | |||||||||
| LUAD | 0.017 | ||||||||
| LUSC | 0.377 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.44 | ||||||||
| PELP1-Ser1093 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.614 | ||||||||
| COAD | 0.447 | ||||||||
| HGSC | -2.437 | ||||||||
| ccRCC | |||||||||
| GBM | 0.646 | ||||||||
| HNSC | 0.519 | ||||||||
| LUAD | 0.258 | ||||||||
| LUSC | 0.525 | ||||||||
| non_ccRCC | |||||||||
| PDAC | 0.675 | ||||||||
| UCEC | -0.019 | ||||||||
| PELP1-Ser1109 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -1.064 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.92 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.145 | ||||||||
| PELP1-Ser1123 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.146 | ||||||||
| HNSC | 0.625 | ||||||||
| LUAD | -0.516 | ||||||||
| LUSC | -0.848 | ||||||||
| non_ccRCC | 0.377 | ||||||||
| PDAC | 1.725 | ||||||||
| UCEC | -1.218 | ||||||||
| PELP1-Ser527 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.414 | ||||||||
| COAD | -1.074 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.343 | ||||||||
| HNSC | -0.269 | ||||||||
| LUAD | -0.158 | ||||||||
| LUSC | -0.99 | ||||||||
| non_ccRCC | 2.19 | ||||||||
| PDAC | 0.28 | ||||||||
| UCEC | 0.777 | ||||||||
| PELP1-Ser531 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.81 | ||||||||
| COAD | -0.691 | ||||||||
| HGSC | 1.726 | ||||||||
| ccRCC | |||||||||
| GBM | -0.525 | ||||||||
| HNSC | -0.36 | ||||||||
| LUAD | -0.371 | ||||||||
| LUSC | -0.911 | ||||||||
| non_ccRCC | 1.866 | ||||||||
| PDAC | -0.078 | ||||||||
| UCEC | 0.154 | ||||||||
| PELP1-Ser535 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -1.092 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.57 | ||||||||
| HNSC | -0.617 | ||||||||
| LUAD | -0.283 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 1.422 | ||||||||
| PELP1-Ser708 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 2.671 | ||||||||
| COAD | -0.319 | ||||||||
| HGSC | -0.323 | ||||||||
| ccRCC | |||||||||
| GBM | 0.171 | ||||||||
| HNSC | -0.151 | ||||||||
| LUAD | -0.297 | ||||||||
| LUSC | -0.321 | ||||||||
| non_ccRCC | -0.562 | ||||||||
| PDAC | -1.035 | ||||||||
| UCEC | 0.165 | ||||||||
| PELP1-Ser793 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.755 | ||||||||
| HGSC | -0.788 | ||||||||
| ccRCC | |||||||||
| GBM | 1.803 | ||||||||
| HNSC | 0.443 | ||||||||
| LUAD | -0.594 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.109 | ||||||||
| PELP1-Thr1064 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | -0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | 0.707 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PELP1-Thr1113 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 1.395 | ||||||||
| HNSC | -0.18 | ||||||||
| LUAD | -0.23 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.985 | ||||||||
| PELP1-Thr1119 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 1.087 | ||||||||
| HNSC | 0.181 | ||||||||
| LUAD | |||||||||
| LUSC | -0.144 | ||||||||
| non_ccRCC | 0.426 | ||||||||
| PDAC | 0.316 | ||||||||
| UCEC | -1.866 | ||||||||
| PELP1-Thr1132 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -2.231 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.597 | ||||||||
| HNSC | 0.33 | ||||||||
| LUAD | |||||||||
| LUSC | 0.056 | ||||||||
| non_ccRCC | 0.264 | ||||||||
| PDAC | 0.504 | ||||||||
| UCEC | 0.481 | ||||||||
| PELP1-Thr1140 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.142 | ||||||||
| COAD | |||||||||
| HGSC | -2.448 | ||||||||
| ccRCC | |||||||||
| GBM | 0.149 | ||||||||
| HNSC | 0.424 | ||||||||
| LUAD | 0.481 | ||||||||
| LUSC | 0.543 | ||||||||
| non_ccRCC | |||||||||
| PDAC | 0.412 | ||||||||
| UCEC | 0.298 | ||||||||
| PELP1-Thr538 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | 1.142 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | -0.719 | ||||||||
| LUAD | -0.423 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PELP1-Thr697 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.289 | ||||||||
| COAD | -0.764 | ||||||||
| HGSC | 0.06 | ||||||||
| ccRCC | |||||||||
| GBM | 1.408 | ||||||||
| HNSC | 0.603 | ||||||||
| LUAD | |||||||||
| LUSC | -0.633 | ||||||||
| non_ccRCC | -1.457 | ||||||||
| PDAC | 0.362 | ||||||||
| UCEC | -0.867 | ||||||||
| PELP1-Thr795 | |
|---|---|
| Cancer | Intensity |
| BRCA | -1.002 |
| COAD | -0.212 |
| HGSC | -2.334 |
| ccRCC | |
| GBM | 0.786 |
| HNSC | 0.895 |
| LUAD | -0.114 |
| LUSC | 0.699 |
| non_ccRCC | 0.55 |
| PDAC | 0.438 |
| UCEC | 0.296 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 1033 | U | Triple-negative breast cancer | Phosphorylation | 25788226 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.709 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.9399 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.5618 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 7.5743 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 8.3848 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | RPMI8226 | BTZ | 8.5681 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | HeLa | Curcumin | 1 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | HeLa | CUDC101 | 4.261 | up | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | ARH-77 | Rituximab | -3.6573 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | PC-9 | LapatinibAZD4547 | 5.8514 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | K562 | Dasatinib | 6.2549 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | MK2206 | 6.7322 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | Tideglusib | 5.7221 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | PD325901 | 8.0433 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | MK2206 | 7.2373 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | Dasatinib | 6.76 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A549 | Dasatinib | 7.3458 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | SelumetinibMK2206-3to1 | 6.2652 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | SelumetinibMK2206-1to2 | 11.0573 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | Selumetinib | 6.5941 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | Selumetinib | 7.2756 | - | |
| Q8IZL8 | PELP1 | P | Ser1033 | GADTAPTLAPEALPS(ph)QGEVER | A459 | MK2206 | 7.5089 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
